Granted Patent
B1
US 12,414,942 · App. 18/939,325 · Granted Sep 16, 2025
Compositions, methods, and systems for treating presbyopia
Assignee:
LENZ THERAPEUTICS OPERATIONS, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides methods comprising administration protocols of an ophthalmological composition, such as comprising aceclidine.
Claims (16)
1. A method of treating presbyopia in an individual, the method comprising administering a first drop of an ophthalmological composition to an eye of the individual and subsequently administering a second drop of the ophthalmological composition to the eye of the individual, the ophthalmological composition comprising aceclidine or a salt thereof, the second drop being administered to the eye of the individual about 2 minutes after the first drop is administered to the eye, wherein the ophthalmological composition comprises aceclidine in a free base concentration of about 1.44 wt. %.
2. A method of treating presbyopia in an individual, the method comprising administering a first drop of an ophthalmological composition to an eye of the individual and subsequently administering a second drop of the ophthalmological composition to the eye of the individual, the ophthalmological composition comprising aceclidine or a salt thereof, the second drop being administered to the eye of the individual about 2 minutes after the first drop is administered to the eye, wherein following administration of the ophthalmological composition to the eye, the individual has 3-lines or more improvement in the eye within 0.5 hours of administering the second drop to the eye, and the individual has 3-lines or more improvement for at least 8 hours in the eye.
3. A method for treating presbyopia, the method comprising instilling one drop of an ophthalmological composition comprising aceclidine or a salt thereof in each eye followed by a second drop in each eye about two (2) minutes later for an effect of at least 10 hours, wherein the ophthalmological composition is preservative-free.
4. A method for treating presbyopia, the method comprising instilling one drop of an ophthalmological composition comprising aceclidine or a salt thereof in each eye followed by a second drop in each eye about two (2) minutes later for an effect of at least 10 hours, wherein no more than a first drop and a second drop of the ophthalmological composition is administered to the eye in a day.
5. The method of claim 1 , wherein following administration of the ophthalmological composition to the eye, the individual has 3-lines or more improvement in the eye within 0.5 hours of administering the second drop to the eye, and the individual has 3-lines or more improvement for at least 8 hours in the eye.
6. The method of claim 1 , wherein the ophthalmological composition is preservative-free.
7. The method of claim 1 , wherein no more than a first drop and a second drop of the ophthalmological composition is administered to the eye in a day.
8. The method of claim 2 , wherein the ophthalmological composition comprises aceclidine in a free base concentration of about 1.44 wt. %.
9. The method of claim 2 , wherein the ophthalmological composition is preservative-free.
10. The method of claim 2 , wherein no more than a first drop and a second drop of the ophthalmological composition is administered to the eye in a day.
11. The method of claim 3 , wherein the ophthalmological composition comprises aceclidine in a free base concentration of about 1.44 wt. %.
12. The method of claim 3 , wherein following administration of the ophthalmological composition to the eye, the individual has 3-lines or more improvement in the eye within 0.5 hours of administering the second drop to the eye, and the individual has 3-lines or more improvement for at least 8 hours in the eye.
13. The method of claim 3 , wherein no more than a first drop and a second drop of the ophthalmological composition is administered to the eye in a day.
14. The method of claim 4 , wherein the ophthalmological composition comprises aceclidine in a free base concentration of about 1.44 wt. %.
15. The method of claim 4 , wherein following administration of the ophthalmological composition to the eye, the individual has 3-lines or more improvement in the eye within 0.5 hours of administering the second drop to the eye, and the individual has 3-lines or more improvement for at least 8 hours in the eye.
16. The method of claim 4 , wherein the ophthalmological composition is preservative-free.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 18, 2024
From: HORN, GERALD
To: LENZ THERAPEUTICS OPERATIONS, INC.
Reel/Frame 069629/0148 →
Continuity (19)
Continuation In Part
18606372
· Mar 15, 2024
Provisional Application
63573626
· Apr 3, 2024
Provisional Application
63565668
· Mar 15, 2024
Provisional Application
63660858
· Jun 17, 2024
Provisional Application
63565672
· Mar 15, 2024
Provisional Application
63573630
· Apr 3, 2024
Provisional Application
63660853
· Jun 17, 2024
Provisional Application
63565674
· Mar 15, 2024
Provisional Application
63573632
· Apr 3, 2024
Provisional Application
63660848
· Jun 17, 2024
Provisional Application
63565679
· Mar 15, 2024
Provisional Application
63573636
· Apr 3, 2024
Provisional Application
63660969
· Jun 17, 2024
Provisional Application
63565687
· Mar 15, 2024
Provisional Application
63573640
· Apr 3, 2024
Provisional Application
63660962
· Jun 17, 2024
Provisional Application
63565692
· Mar 15, 2024
Provisional Application
63573641
· Apr 3, 2024
Provisional Application
63660959
· Jun 17, 2024
References Cited (265)
US 4474751A
· Haslam et al.
· 1984
[cited by applicant]
US 4906467A
· Schwartzman et al.
· 1990
[cited by applicant]
US 5073560A
· Wu et al.
· 1991
[cited by applicant]
US 5286864A
· Walther et al.
· 1994
[cited by applicant]
US 5451587A
· Walther et al.
· 1995
[cited by applicant]
US 5488050A
· Neufeld
· 1996
[cited by applicant]
US 6120758A
· Siddiqui et al.
· 2000
[cited by applicant]
US 6241124B1
· Hoyt
· 2001
[cited by applicant]
US 6291466B1
· Gwon et al.
· 2001
[cited by applicant]
US 6353022B1
· Schneider et al.
· 2002
[cited by applicant]
US 6410544B1
· Gwon et al.
· 2002
[cited by applicant]
US 7067261B2
· Bencherif et al.
· 2006
[cited by applicant]
US 8299079B2
· Kaufman
· 2012
[cited by applicant]
US 8455494B2
· Kaufman
· 2013
[cited by applicant]
US 8501800B2
· Bowman et al.
· 2013
[cited by applicant]
US 8524758B2
· Benozzi
· 2013
[cited by applicant]
US 9089562B2
· Horn et al.
· 2015
[cited by applicant]
US 9314427B2
· Horn et al.
· 2016
[cited by applicant]
US 9320709B2
· Horn et al.
· 2016
[cited by applicant]
US 9833441B2
· Horn et al.
· 2017
[cited by applicant]
US 9844537B2
· Horn et al.
· 2017
[cited by applicant]
US 9968594B2
· Horn et al.
· 2018
[cited by applicant]
US 20020035264A1
· Kararli et al.
· 2002
[cited by applicant]
US 20030104996A1
· Li et al.
· 2003
[cited by applicant]
US 20030140996A1
· Thomson
· 2003
[cited by applicant]
US 20030165545A1
· Huth et al.
· 2003
[cited by applicant]
US 20040106644A1
· Randazzo
· 2004
[cited by applicant]
US 20050196370A1
· Yu et al.
· 2005
[cited by applicant]
US 20060172972A1
· Bhushan et al.
· 2006
[cited by applicant]
US 20060177430A1
· Bhushan et al.
· 2006
[cited by applicant]
US 20070297990A1
· Shah et al.
· 2007
[cited by applicant]
US 20090156581A1
· Dillon et al.
· 2009
[cited by applicant]
US 20090297566A1
· Brinkman et al.
· 2009
[cited by applicant]
US 20110250294A1
· Tien et al.
· 2011
[cited by applicant]
US 20110251285A1
· Tien et al.
· 2011
[cited by applicant]
US 20120028910A1
· Combal et al.
· 2012
[cited by applicant]
US 20120315265A1
· Lai et al.
· 2012
[cited by applicant]
US 20130245030A1
· Kaufman
· 2013
[cited by applicant]
US 20140378401A1
· Horn
· 2014
[cited by applicant]
US 20150010634A1
· Knappe et al.
· 2015
[cited by applicant]
US 20160018671A1
· Waite et al.
· 2016
[cited by applicant]
US 20180235946A1
· Horn et al.
· 2018
[cited by applicant]
US 20190038609A1
· Horn
· 2019
[cited by applicant]
US 20190240152A1
· Horn et al.
· 2019
[cited by applicant]
US 20200308168A1
· Banerjee et al.
· 2020
[cited by applicant]
US 20210251970A1
· Horn
· 2021
[cited by applicant]
US 20220031608A1
· Horn
· 2022
[cited by applicant]
US 20220105090A1
· Horn
· 2022
[cited by applicant]
US 20220233434A1
· Horn
· 2022
[cited by applicant]
US 20220347170A1
· Horn
· 2022
[cited by applicant]
US 20230190738A1
· Horn
· 2023
[cited by applicant]
US 20230190739A1
· Horn
· 2023
[cited by applicant]
US 20230248644A1
· Horn
· 2023
[cited by applicant]
US 20230310392A1
· Horn
· 2023
[cited by applicant]
US 20230398113A1
· Horn
· 2023
[cited by applicant]
US 20230404912A1
· Horn
· 2023
[cited by applicant]
US 20230414494A1
· Horn
· 2023
[cited by applicant]
CN 101262886A
· 2008
[cited by applicant]
CN 101616640A
· 2009
[cited by applicant]
EP 0197718A2
· 1986
[cited by applicant]
JP S62194861A
· 1987
[cited by applicant]
JP H06211666A
· 1994
[cited by applicant]
JP H07330604A
· 1995
[cited by applicant]
JP 2852607B2
· 1999
[cited by applicant]
JP H11292151A
· 1999
[cited by applicant]
JP 2002521429A
· 2002
[cited by applicant]
JP 2004168709A
· 2004
[cited by applicant]
JP 2008536866A
· 2008
[cited by applicant]
JP 2010514517A
· 2010
[cited by applicant]
JP 2012508793A
· 2012
[cited by applicant]
WO WO9612711A1
· 1996
[cited by applicant]
WO WO0006135A2
· 2000
[cited by applicant]
WO WO02080915A2
· 2002
[cited by applicant]
WO WO02100437A2
· 2002
[cited by applicant]
WO WO2007011874A2
· 2007
[cited by applicant]
WO WO2008083118A1
· 2008
[cited by applicant]
WO WO2009015286A2
· 2009
[cited by applicant]
WO WO2009077736A2
· 2009
[cited by applicant]
WO WO2010070664A1
· 2010
[cited by applicant]
WO WO2010125416A1
· 2010
[cited by applicant]
WO WO2010135731A1
· 2010
[cited by applicant]
WO WO2012119070A2
· 2012
[cited by applicant]
WO WO2013041967A2
· 2013
[cited by applicant]
WO WO2014161002A2
· 2014
[cited by applicant]
WO WO2015031186A1
· 2015
[cited by applicant]
WO WO2015031187A1
· 2015
[cited by applicant]
WO WO2015094392A1
· 2015
[cited by applicant]
WO WO2016205068A1
· 2016
[cited by applicant]
WO WO2016205069A1
· 2016
[cited by applicant]
WO WO2016205071A1
· 2016
[cited by applicant]
WO WO2017053646A1
· 2017
[cited by applicant]
WO WO2017160548A1
· 2017
[cited by applicant]
WO WO2019135927A1
· 2019
[cited by applicant]
WO WO2020076769A1
· 2020
[cited by applicant]
WO WO2020117637A1
· 2020
[cited by applicant]
WO WO2020219707A1
· 2020
[cited by applicant]
WO WO2022081204A1
· 2022
[cited by applicant]
WO WO2022232205A1
· 2022
[cited by applicant]
WO WO2023091439A1
· 2023
[cited by applicant]
WO WO2023114347A1
· 2023
[cited by applicant]
WO WO2024220441A1
· 2024
[cited by applicant]
White, (Ophthalmology, vol. 98, Issue 3), pp. 367-389. (Year: 1991).
[cited by examiner]
Glaucoma Research Foundation (Year: 2022).
[cited by examiner]
Presbyopia, Mayo Foundation for Medical Education. (Year: 1998).
[cited by examiner]
Aceclidine (Hydrochloride) Item No. 1790. Product Information. Cayman Chemical Company (1 pg) (Dec. 2, 2022).
[cited by applicant]
Akorn Incorporated MSDS: Tropicacyl (R); Rev. 11-11 (date unknown).
[cited by applicant]
Barot et al. Prodrug Strategies. Ocular Drug Delivery Med. Chem. 8(4):753-768 (2012).
[cited by applicant]
Berge, Stephen M. et al. Pharmaceutical Salts. Journal of Pharmaceutical Sciences 66(1):1-19 (1977).
[cited by applicant]
Bijsluiter: Glaucocare. Available at https://consumed.nl/bijsluiters/glaucocare. Machine Translation Provided (Retrieved Sep. 12, 2018).
[cited by applicant]
CAS printout for Mashkovskii, The Relation Between the Chemical Structure and Pharmacological Activity of Some Esters of 3-Hydroxyquinuclidine (Quinuclidine-3-ol), Proc. Intern. Pharmacol., 7:359-366 (1961).
[cited by applicant]
Charman, W. Neil. Pinholes and presbyopia: solution or sideshow? Ophthalmic Physiol Opt 39(1):1-10 (2019).
[cited by applicant]
Chung et al., The effect of dioptric blur on reading performance. Vision Res47(12):1584-94 (2007).
[cited by applicant]
Co-pending U.S. Appl. No. 18/606,372, inventor Horn; Gerald, filed Mar. 15, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/606,417, inventor Horn; Gerald, filed Mar. 15, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/606,433, inventor Horn; Gerald, filed Mar. 15, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/606,475, inventor Horn; Gerald, filed Mar. 15, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/606,489, inventor Horn; Gerald, filed Mar. 15, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/606,509, inventor Horn; Gerald, filed Mar. 15, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/753,403, inventors Olsson; Shawn et al., filed Jun. 25, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/763,722, inventors Horn; Gerald et al., filed Jul. 3, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/765,066, inventors Horn; Gerald et al., filed Jul. 5, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/765,156, inventors Horn; Gerald et al., filed Jul. 5, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/766,429, inventors Horn; Gerald et al., filed Jul. 8, 2024.
[cited by applicant]
Cowan et al., Clinical evaluation of a new mydriatic-mydrilate. Br J Ophthalmol 46(12):730-6 (1962).
[cited by applicant]
Davidson., General medicine and visual side effects. Br Med J 1(6166):821 (1979).
[cited by applicant]
Diamonds—BCdVA and Refraction Guideline, Version 1.0, Jan. 12, 2016 (10 pages).
[cited by applicant]
Drance et al., Dose response of human intraocular pressure to aceclidine. Arch Ophthalmol 88(4):394-6 (1972).
[cited by applicant]
Drug information Q&A “Q29”. What is the expiry date of drugs and how to store them properly?, Japan Pharmaceutical Manufacturers Association [online], Mar. 2014, [retrieved on Mar. 25, 2024], Retrieved from the Internet…
[cited by applicant]
Edwards., Behaviour of the fellow eye in acute angle-closure glaucoma. Br J Ophthalmol 66(9):576-9 (1982).
[cited by applicant]
Edwards et al., Effect of brimonidine tartrate 0.15% on night-vision difficulty and contrast testing after refractive surgery, J Cataract Refract Surg. 34(9):1538-41 (2008).
[cited by applicant]
Ehlert et al. The interaction of the enantiomers of aceclidine with subtypes of the muscarinic receptor. J Pharmacol Exp Ther 279(3):1335-1344 (1996).
[cited by applicant]
Fechner et al., Accomodative effects of aceclidine in the treatment of glaucoma. Amer J Ophth. 79 (1):104-106 (1975).
[cited by applicant]
Francois et al. Ultrasonographic study of the effect of different miotics on the eye components. Ophthalmologica 175(6):328-338 (1977).
[cited by applicant]
Fricke et al. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia: Systematic Review, Meta-analysis, and Modelling. Ophthalmology 125(10):1492-1499 (2018).
[cited by applicant]
Gardiner., ABC of Ophthalmology: accidents and first aid. Br Med J 2(6148):1347-50 (1978).
[cited by applicant]
Gardiner., ABC of Ophthalmology: Methods of examination. Br Med J 2(6152):1622-6 (1978).
[cited by applicant]
Glaucadrine, poudre et solvant pour collyre en solution, boite de 1 acon de lyophilisat + acon le solvant de 10 ml GI. Available at Http://www.doctissimo.fr/medicament-GLAUCADRINE.htm Machine translation provided (Retri…
[cited by applicant]
Glaunorm toma all'Indice farmaci. Available at http://www.anibaldi.eu/farmaci/schedetecniche/GLAUNORM.html. Machine Translation Provided (last updated Dec. 15, 2012).
[cited by applicant]
Grünberger et al., The pupillary response test as a method to differentiate various types of dementia. Neuropsychiatr 23(1):52-57 (2009).
[cited by applicant]
Hoyng et al., The combination of guanethidine 3% and adrenaline 0.5% in 1 eyedrop (GA) in glaucoma treatment. Br J Ophthalmol 63(1):56-62 (1979).
[cited by applicant]
Ishikawa et al. Selectivity of muscarinic agonists including (+/−)-aceclidine and antimuscarinics on the human intraocular muscles. J Ocul Pharmacol Ther 14(4):363-373 (1998).
[cited by applicant]
Jiao, Jim. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Advanced Drug Delivery Reviewed 60:1663-1673 (2008).
[cited by applicant]
Kaufman et al. Presbyopia and Glaucoma: Two Diseases, One Pathophysiology? The 2017 Friedenwald Lecture. Invest Ophthalmol Vis Sci 60(5):1801-1812 (2019).
[cited by applicant]
Kibbe, Arthur H. Handbook of Pharmaceutical Excipients. 3rd Edition. American Pharmaceutical Association and Pharmaceutical Press :416-419 (2000).
[cited by applicant]
Krise et al. A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. J Pham Sci 88(9):922-927 (1999).
[cited by applicant]
Latanoprost Label (2006).
[cited by applicant]
Lubrizol Pharmaceutical Bulletin 21 (Lubrizol Advanced Materials, Inc.) May 31, 2011.
[cited by applicant]
Mayama et al. Myopia and advanced-stage open-angle glaucoma. Ophthalmology 109(11):2072-2077 (2002).
[cited by applicant]
Mayo Clinic: Tropicamide (Opthalmic Route). Available at, http://www.mayoclinic.org/drugs-supplements/tropicamide-ophthalmic-route/description/drg-20066481 (Retrieved on Dec. 2014).
[cited by applicant]
Mäntylä et al. Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone. Eur J Pharm Sci 23(2):151-158 (2004).
[cited by applicant]
Mohan et al., Optimal dosage of cyclopentolate 1% for cycloplegic refraction in hypermetropes with brown irides. Indian J Ophthalmol 59(6):514-6 (2011).
[cited by applicant]
Muller and R.P. Dessing (Eds.) 4th Edition, European Drug Index, European Society of Clinical Pharmacy, Jeutscher Apotheker Verlag Suttgart (p. 550) (1997).
[cited by applicant]
Nayak et al., A comparison of cycloplegic and manifest refractions on the NR-1000F (an objective Auto Refractometer). Br J Ophthalmol 71(1):73-5 (1987).
[cited by applicant]
Park., The comparison of mydriatic effect between two drugs of different mechanism. Korean J Ophthalmol 23(1):40-2 (2009).
[cited by applicant]
PCT/US2014/052256 International Search Report and Written Opinion dated Dec. 18, 2014.
[cited by applicant]
PCT/US2016/036687 International Search Report and Written Opinion dated Sep. 9, 2016.
[cited by applicant]
PCT/US2016/036692 International Search Report and Written Opinion dated Sep. 22, 2016.
[cited by applicant]
PCT/US2016/036694 International Search Report and Written Opinion dated Oct. 26, 2016.
[cited by applicant]
PCT/US2017/021244 International Search Report and Written Opinion dated May 22, 2017.
[cited by applicant]
PCT/US2019/055116 International Search Report and Written Opinion dated Dec. 19, 2019.
[cited by applicant]
PCT/US2019/063923 International Invitation to Pay Additional Fees dated Feb. 3, 2020.
[cited by applicant]
PCT/US2019/063923 International Search Report and Written Opinion dated Apr. 23, 2020.
[cited by applicant]
PCT/US2021/029536 International Search Report and Written Opinion dated Aug. 9, 2021.
[cited by applicant]
PCT/US2022/026435 International Invitation to Pay Additional Fees dated Jul. 5, 2022.
[cited by applicant]
PCT/US2022/026435 International Search Report and Written Opinion dated Sep. 28, 2022.
[cited by applicant]
PCT/US2022/050028 International Search Report and Written Opinion dated Mar. 2, 2023.
[cited by applicant]
PCT/US2024/024819 International Search Report and Written Opinion dated Jul. 15, 2024.
[cited by applicant]
Pramanik et al. A new route to cevimeline. Tetrahedron Letters 54(24):3043-3045 (2013).
[cited by applicant]
Primožič et al. Influence of the acyl moiety on the hydrolysis of quinuclidinium esters catalyzed by butyrylcholinesterase. Croatica Chemica Acta 84(2):245-249 (2011).
[cited by applicant]
Prospectus/Technical Sheet for Glaucostat Josefa Valcarecel Glaucostat® 2% colirio (2000).
[cited by applicant]
PubChem 233021624 deposited on Feb. 12, 2015.
[cited by applicant]
PubChem 427198483 deposited Aug. 13, 2020 (Aug. 13, 2020).
[cited by applicant]
PubChem CID-22416839, Dec. 5, 2007.
[cited by applicant]
PubChem-CID-22416839, Create Date: Dec. 5, 2007 (Modified Jul. 15, 2023).
[cited by applicant]
Randazzo et al., Pharmacological management of night vision disturbances after refractive surgery Results of a randomized clinical trial. J Cataract Refract Surg 31(9):1764-1772 (2005).
[cited by applicant]
Romano., Double-blind cross-over comparison of aceclidine and pilocarpine in open-angle glaucoma. Br J Ophthalmol 54(8):510-21 (1970).
[cited by applicant]
Santvliet, et al. Determinants of Eye Drop Size. Survey of Ophthamology 49(2):197-213 (2004).
[cited by applicant]
Schuster, Bradley L. Is There a Best Technique for Putting in Eye Drops ?. Glaucoma Research Foundation, Mar. 23, 2022; [retrieved on Jun. 14, 2024]. Available at URL: https://glaucoma.org/articles/is-there-a-best-techn…
[cited by applicant]
Smith et al., Subsensitivity to cholinoceptor stimulation of the human iris sphincter in situ following acute and chronic administration of cholinomimetic miotic drugs. Br J Pharmacol 69(3):513-8 (1980).
[cited by applicant]
Stella. Prodrugs: Some Thoughts and Current Issues. J Pharm Sci 99(12):4755-4765 (2010).
[cited by applicant]
Tataru et al., Antiglaucoma pharmacotherapy. J Med Life 5(3):247-51 (2012).
[cited by applicant]
Trinavarat et al., Effective pupil dilatation with a mixture of 0.75% tropicamide and 2.5% phenylephrine: A randomized controlled trial. Indian J Ophthalmol 57(5):351-4 (2009).
[cited by applicant]
U.S. Appl. No. 18/606,372 Office Action dated Jun. 20, 2024.
[cited by applicant]
U.S. Appl. No. 18/606,372 Restriction Requirement dated Jun. 4, 2024.
[cited by applicant]
U.S. Appl. No. 18/606,417 Office Action dated Jun. 13, 2024.
[cited by applicant]
U.S. Appl. No. 18/606,433 Office Action dated Jun. 26, 2024.
[cited by applicant]
U.S. Appl. No. 18/606,475 Office Action dated Jul. 10, 2024.
[cited by applicant]
U.S. Appl. No. 18/606,475 Restriction Requirement dated May 9, 2024.
[cited by applicant]
U.S. Appl. No. 18/606,509 Restriction Requirement dated May 13, 2024.
[cited by applicant]
Valcarcel, Josefa. Glaucostat(R) 2% colirio. Machine translation provided (Retrieved Oct. 10, 2023).
[cited by applicant]
Varma et al. Concentration of Latanoprost Ophthalmic Solution after 4 to 6 Weeks' Use in an Eye Clinic Setting. Invest Ophthalmol Vis Sci. 47(1):222-225 (2006).
[cited by applicant]
Ward et al., 1,2,5-Thiadiazole analogues of aceclidine as potent ml muscarinic agonists. J Med Chem 41(3):379-392 (1988).
[cited by applicant]
White, et al. Effect of Blinking on Tear Elimination as Evaluated by Dacryoscintigraphy. Ophthalmology 98(3):367-369 (1991).
[cited by applicant]
Wood et al., Pupil dilatation does affect some aspects of daytime driving performance. Br J Ophthalmol (11):1387-90 (2003).
[cited by applicant]
Xu, Renfeng et al. Effect of Target Luminance on Optimum Pupil Diameter for Presbyopic Eyes. Optom Vis Sci 93(11):1409-1419 (2016).
[cited by applicant]
Zhang et al. Reactive impurities in large and small molecule pharmaceutical excipients—A review. TrAC Trends in Analytical Chemistry 101:34-42 (2018).
[cited by applicant]
Zimmerman et al. Side Effects and Ways to Avoid Them. Ophthalmology 89(1):P76-80 (1982).
[cited by applicant]
Presbyopia, Treatment of Presbyopia Mayo Foundation for Medical Education. (Year: 1998).
[cited by applicant]
U.S. Appl. No. 17/552,694 Office Action dated Feb. 12, 2025.
[cited by applicant]
U.S. Appl. No. 18/606,372 Office Action dated Jan. 7, 2025.
[cited by applicant]
Barman, Purna Chandra et al. An Overview of Non-Newtonian Fluid. International Journal of Applied Science and Engineering 4(2):97-101 (2016).
[cited by applicant]
PubChem SID 500830745. Talsaclidine. Available from: https://pubchem.ncbi.nlm.nih.gov/substance/500830745 (2024).
[cited by applicant]
U.S. Appl. No. 17/730,376 Office Action dated Mar. 7, 2025.
[cited by applicant]
U.S. Appl. No. 18/369,737 Office Action dated Mar. 28, 2025.
[cited by applicant]
PCT/US2025/019824 International Search Report and Written Opinion dated May 20, 2025.
[cited by applicant]
PCT/US2025/019822 International Search Report and Written Opinion dated May 20, 2025.
[cited by applicant]
PCT/US2025/019809 International Search Report and Written Opinion dated May 20, 2025.
[cited by applicant]
PCT/US2025/019828 International Search Report and Written Opinion dated May 20, 2025.
[cited by applicant]
PCT/US2025/019866 International Search Report and Written Opinion dated May 20, 2025.
[cited by applicant]
PCT/US2025/019860 International Search Report and Written Opinion dated May 20, 2025.
[cited by applicant]